Zusammenfassung
Amiodaron, ein Benzofuranderivat, wurde 1961 bei Labaz entwickelt (1, 2) und ursprünglich als antianginöse wirksame Substanz in die Klinik eingeführt (3, 4). Erst später wurden die potenten antiarrhythmischen Eigenschaften der Substanz bekannt, die der Klasse III nach Vaughan-Williams zuzuordnen sind (5–7). Inzwischen liegen zahlreiche Studien vor, die die Wirksamkeit von Amiodaron bei einer Vielzahl therapierefraktärer supraventrikulärer und ventrikulärer Tachyarrhythmien belegen (8–32). Die pharmakologischen Eigenschaften von Amiodaron mit einer langen Halbwertzeit erleichtern zwar die chronische Einnahme, bedingen andererseits aber auch Probleme bei der Wahl seiner optimalen Aufsättigungs- und Erhaltungsdosis. Diese komplexen Zusammenhänge und die potentiell ernsten Nebenwirkungen (16, 33–34) lassen Amiodaron zu einer Sustanz werden, die nur bei bedrohlichen Tachyarrhythmien, die sich gegenüber anderen, konventionellen Antiarrhythmika als ineffektiv erwiesen haben, eingesetzt werden sollte.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Charlier R, Deltour G, Tondeur R, Binon F (1962) Recherches dans la serie des benzofurannes. VII. Etude pharmacoligique préliminaire due butyl-2 (diiode-3′, 5′-beta-N-diethylamino-ethoxy-4′ benzoyl)-3 bezonfu- ranne. Arch Intern Pharmacodyn Ther 139: 255–264
Charlier R, Delaunois G, Bautheri J et al (1969) Dans la serie des benzofurannes. XL. Properties antiarrhythmiques de amiodarone. Cardiologia 54: 82
Charlier R, Deltaur G, Baudine A (1968) Pharmacology of amiodarone, an antianginal drug with new biologic profile. Arzneimittelforsch 18: 1408
Vastesaeger M, Gillot P, Rassons G (1967) Etude clinique d’une nouvelle médication antiangoreuse. Acta Cardiol (Belgium) 22: 483: 500
Singh B, Vaughan Williams E (1970) The effect of amiodarone, a new antianginal drug on cardiac muscle. Br J Pharmacol 39: 657
Rosenbaum M, Chiale P, Halpern M (1976) Clinical efficacy of amiodarone as an antiarrhythmic agent. Am J Cardiol 38: 934
Sing BN, Collet J, Chow C (1980) New perspectives in the pharmacologic therapy of cardiac arrhythmias. Prog Cardiovasc Dis 22: 243
Nademanee K, Hendrickson, J, Cannom DS et al (1981) Control of refractory life-threatening ventricular tachyarrhythmias by amiodarone. Am Heart J 6: 759
Heger JJ, Prystowsky EN, Jackman WM et al (1981) Amiodarone. Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation. N Engl J Med 305: 539
Hamer AW, Finerman WB, Peter T et al (1981) Disparity between the clinical and electrophysiologic effects of amiodarone in the treatment of recurrent ventricular tachyarrhythmias. Am Heart J 102: 992
Waxman HL, Groh WC, Marchlinski FE et al (1982) Amiodarone for control of sustained ventricular tachyarrhythmia: Clinical and electrophysiologic effects in 51 patients. Am J Cardiol 50: 1066
Saksena S, Rothbart ST, Cappello G (1983) Chronic effects of amiodarone in patients with refractory ventricular tachycardia. Int J Cardiol 3: 339
Nademanee K, Singh BN, Hendrickson J et al (1983) Amiodarone in refractory life-threatening ventricular arrhythmias. Ann Intern Med 98: 577
Haffajee CI, Love JC, Canada AT et al (1983) Clinical pharmacokinetics and efficacy of amiodarone for refractory tachyarrhythmias. Circulation 67: 1347
Morady F, Sauve MJ, Maline P et al (1983) Long-term efficacy and toxicity of high dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation. Am J Cardiol 52: 975
Greene HL, Graham EL, Werner JA et al (1983) Toxic and therapeutic effects of amiodarone in the treatment of cardiac arrhythmias. J Am Coll Cardiol 2: 1114
McGovern B, Garan H, Malacoff RF et al (1984) Long-term clinical outcome of ventricular tachycardia or fibrillation treated with amiodarone. Am J Cardiol 53: 1558
Marchlinski FE, Buxton AE, Flores BT et al (1985) Value of Holter monitoring in identifying risk for sustained ventricular arrhythmia recurrence on amiodarone. Am J Cardiol 55: 709
Horowitz LN, Greenspan AM, Spielman SR et al (1985) Usefulness of electrophysiologic testing in evaluation of amiodarone therapy for sustained ventricular tachyarrhythmias associated with coronary heart disease. Am J Cardiol 55: 367
Reddy CP, Kuo CS, Jivraijka V (1984) Effect of amiodarone on electric induction, morphology, and rate of ventricular tachycardia and its relation to clinical efficacy. PACE 7: 1055
Veltri EP, Reid PR, Platia EV et al (1985) Results of late programmed electrical stimulation and long-term electrophysiologic effects of amiodarone therapy in patients with refractory ventricular tachycardia. Am J Cardiol 55: 375
Veltri EP, Reid PR, Platia EV et al (1985) Amiodarone in the treatment of life-threatening ventricular tachycardia: Role of Holter monitoring in predicting long-term clinical efficacy. J Am Coll Cardiol 6: 806
Naccarelli GV, Fineberg NA, Zipes DP et al (1985) Amiodarone: Risk factors for recurrence of symptomatic ventricular tachycardia identified at electrophysiologic study. J Am Coll Cardiol 6: 814
Morady F, Scheinman MM, Hess DS (1983) Amiodarone in the management of patients with ventricular tachycardia and ventricular fibrillation. PACE 6: 609
Sokoloff NN, Spielman SR, Greenspan AM et al (1986) Utility of ambulatory electrocardiographic monitoring for predicting recurrence of sustained ventricular tachyarrhythmias in patients receiving amiodarone. J Am Coll Cardiol 7: 938
DiCarlo LA Jr, Morady F, Sauve MJ et al (1985) Cardiac arrest and sudden death in patients treated with amiodarone for sustained ventricular tachycardia or ventricular fibrillation: Risk stratification based on clinical variables. Am J Cardiol 55: 372
Borggrefe M, Breithardt G (1986) Predictive value of electrophysiologic testing in the treatment of drug- refractory ventricular arrhythmias with amiodarone. European Heart J 7: 735–742
Alboni P, Shantha N, Pirani R, Baggioni F, Scarfo’ S, Tomasi AM, Masoni A (1984) Effects of amiodarone on supraventricular tachycardia involving bypass tracts. Am J Cardiol 53: 93–98
Feld GK, Nademanee K, Weiss J, Stevenson W, Singh BN (1984) Electrophysiologic basis for the suppression by amiodarone of orthodromic supraventricular tachycardias complicating pre-excitation syndromes. J Am Coll Cardiol 3: 1298–1307
Rowland E, Krikler D (1980) Electrophysiological assessment of amiodarone in treatment of resistant supraventricular arrhythmias. Br Heart J 44: 82–90
Wellens HJJ, Brugada P, Abdullah H (1983) Effect of amiodarone in paroxysmal supraventricular tachycardia with or without Wolff-Parkinson-White syndrom. Am Heart J 106: 876–879
Brugada P, Wellens HJJ (1985) Effects of oral amiodarone on rate-dependent changes in refractoriness in patients with Wolff-Parkinson-White syndrome. Am J Cardiol 56: 863–866
Harris L, McKenna WJ, Rowland E, Holt DW, Storey GCA, Krikler DM (1983) Side effects of long-term amiodarone therapy. Circulation 67: 45–51
Raeder EA, Podrid PJ, Lown B (1985) Side effects and complications of amiodarone therapy. Am Heart J 109: 975
Lavery D, Saksena S, Gordon S et al (1986) Long-term efficacy of amiodarone therapy in refractory sustained ventricular tachycardia: The role of electrophysiologic studies and ambulatory monitoring. J Am Coll Cardiol 7: 91A (Abstr)
Kennedy EE, Batsford WP, Rosenfled LE et al (1984) Predicting therapeutic efficacy with amiodarone: a combined Holter/electrophysiologic approach. J Am Coll Cardiol 3: 605
Chua W, Roth H, Summers C et al (1983) Programmed stimulation versus ambulatory monitoring for therapy of malignant arrhythmias. Circulation 68: III–55
Kim SG, Felder SD, Figeura I et al (1986) Predictive accuracies of Holter monitoring and programmed stimulation in patients taking amiodarone. J Am Coll Cardiol 7: 143 A (Abstr)
Stamato NJ, Marchlinski FE (1986) Role of Holter monitoring in the management of patients with ventricular tachycardia treated with amiodarone. Clin Prog Electrophysiol Pacing 4: 395–401
Denes P, Wu D, Dhingra RC, Amat-y-Leon F, Wyndham C, Mautrer RK, Rosen KM (1976) Electrophysiolical studies in patients with chronic recurrent ventricular tachycardia. Circulation 54: 229–236
Josephson ME, Horowitz LN, Farshidi A, Kastor JA (1978) Recurrent sustained ventricular tachycardia. 1. Mechanismus. Circulation 57: 431–440
Fisher JD, Cohen HL, Mehra R, Altschuler H, Eschwer DJW, Furman S (1977) Cardiac pacing and pacemakers. II. Serial electrophysiologic-pharmacologic testing for control of recurrent tachyarrhythmias. Am Heart J 93: 658–668
Hartzler GO, Maloney JD (1977) Programmed ventricular stimulation in management of recurrent ventricular tachycardia. Mayo Clin Proc 52: 731–741
Wu D, Wyndham CR, Denes P, Amat-y-Leon F, Miller RH, Dhingra RC, Rosen KM (1977) Chronic electrophysiological study in patients with recurrent paroxysmal tachycardia: a new method for developing successful oral antiarrhythmic therapy. In: Kulbertus HE (Ed) (1977) Re-entrant arrhythmias. Mechanisms and treatment. MTP Lancaster, 294–311
Horowitz LN, Josephson ME, Farshidi A, Spielman SR, Michelson EL, Greenspan AN (1978) Recurrent sustained ventricular tachycardia. 3. Role of the electrophysiologic study in selection of antiarrhythmic regimens. Circulation 58: 986–997
Mason JW, Winkle RA (1978) Electrode catheter arrhythmia induction in the selection and assessment of antiarrhythmic drug therapy for recurrent ventricular tachycardia. Circulation 58: 971–985
Breithardt G, Seipel L, Abendroth R-R, Loogen F (1980) Serial electrophysiological testing of antiarrhythmic drug efficacy in patients with recurrent ventricular tachycardia. Europ Heart J 1: 11–24
Denes P, Wu D, Wyndham C, Dhingra R, Bauernfeind RA, Swiryn S, Rosen KM (1980) Chronic long-term electrophysiologic study of paroxysmal ventricular tachycardia. Chest 77: 478–487
Horowitz LN, Josephson ME, Kastor J A (1980) Intracardiac electrophysiologic studies as a method for the optimization of drug therapy in chronic ventricular arrhythmia. Prog Cardiovasc Dis 23: 81–98
Mason J, Winkle RA (1980) Accuracy of the ventricular tachycardia-induction study for predicting long-term efficacy of antiarrhythmic drugs. N Engl J Med 303: 1073–1077
Swerdlow CH, Winkle RA, Mason JA (1983) Determinants of survival in patients with ventricular tachyarrhythmias. N Engl J Med 308: 1436–1442
Borggrefe M, Breithardt G (1986) Abgestufte Kriterien zur Beurteilung der Effektivität einer antiarrhythmi- schen Therapie bei Patienten mit ventrikulären Tachyarrhythmien mittels serieller elektrophysiologischer Testung. Z Kardiol 75: 70–79
Wyndham CR, Krafchek J, Nielsen A, Hargis J, Velasco CE, Magro S (1985) Improved prediction of outcome by serial electrophysiologic tests on amiodarone. Circulation 72 suppl-III: 273 (Abstract)
Borggrefe M, Podczeck A, Breithardt G (1986) Usefulness of early versus late electrophysiologic testing in patients with ventricular tachyarrhythmias treated with amiodarone. Circulation 74 suppl-II: 223 (Abstract)
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Dr. Dietrich Steinkopff Verlag, GmbH & Co. KG, Darmstadt
About this paper
Cite this paper
Borggrefe, M., Podczeck, A., Breithardt, G. (1987). Klinisch-elektrophysiologische Effekte von Amiodaron bei bedrohlichen ventrikulären Tachyarrhythmien. In: Steinbeck, G. (eds) Lebensbedrohliche ventrikuläre Herzrhythmusstörungen. Steinkopff. https://doi.org/10.1007/978-3-642-72405-3_18
Download citation
DOI: https://doi.org/10.1007/978-3-642-72405-3_18
Publisher Name: Steinkopff
Print ISBN: 978-3-642-72406-0
Online ISBN: 978-3-642-72405-3
eBook Packages: Springer Book Archive